CCIA
AKBA icon

Campbell & Co Investment Adviser’s Akebia Therapeutics AKBA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,515
Closed -$160K – 519
2019
Q1 		$160K Buy
+19,515
New +$134K 0.08% 472
2018
Q1 		– Sell
-10,075
Closed -$150K – 350
2017
Q4 		$150K Sell
10,075
-98
-1% -$1.63K 0.11% 347
2017
Q3 		$200K Buy
+10,173
New +$156K 0.16% 297

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's AKBA Position: Q2 2019 in Review

Campbell & Co Investment Adviser sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 19,515 shares — an estimated $160K sold.

Campbell & Co Investment Adviser first reported a position in AKBA in Q3 2017 and held it in 3 quarters. The position peaked at $200K in Q3 2017. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Campbell & Co Investment Adviser reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 19,515 Akebia Therapeutics shares in Q2 2019, an estimated $160K.
  • Campbell & Co Investment Adviser first reported a position in Akebia Therapeutics in Q3 2017 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Akebia Therapeutics position peaked at $200K in Q3 2017.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2019, filed 10 Jul 2019.